Roy Swagnik, Laldinmawii Gracy, Patki Swati M, Sundaram Shanthosh P
Department of Community Medicine, Zoram Medical College, Falkawn, Mizoram, India.
Department of Microbiology, Zoram Medical College, Falkawn, Mizoram, India.
J Family Med Prim Care. 2022 Oct;11(10):6375-6379. doi: 10.4103/jfmpc.jfmpc_506_22. Epub 2022 Oct 31.
In response to this coronavirus disease 2019 (COVID-19) pandemic, vaccines reaching the predetermined levels of safety and efficacy were rolled out for use under emergency use approval/listing (EUA/EUL). The government of India has introduced three vaccines for emergency use as of today.
The study was conducted to evaluate the association between the Covishield vaccine and COVID-19 infection among adults (≥45 years) who undergo reverse transcription-polymerase chain reaction (RT-PCR) COVID-19 testing.
The study was conducted in a dedicated COVID-19 hospital in a north-eastern state of India among adults aged 45 years and above, who underwent RT-PCR testing. Cases were those who tested positive for RT-PCR and controls were those who were RT-PCR negative during the same period. A structured questionnaire was used to collect relevant data pertaining to socio-demographic profile, symptoms of COVID-19, vaccination status, co-morbidities, etc. Multiple logistic regression was used to calculate the odds ratio (OR) to find the association between vaccination and COVID-19 infection.
A total of 116 participants, 45 years and above were interviewed in the study. It was found that cases were more likely to have symptoms (48% vs. 6.9%, value = <0.005) and have history of positive family member (89.7% vs. 72.4%, value = 0.018) than controls. The odds of having COVID-19 infection were OR 12.60 (95% confidence interval (CI) 4.03-39.34) for those that have symptoms and OR 6.07 (95% CI 1.90-19.34) for unvaccinated individuals.
Covishield vaccine protected individuals against COVID-19 infection with the risk of getting the infection being significantly lower in vaccinated individuals. Relevance for Patients: COVID-19 vaccination prevents the infection and addresses misconceptions about the vaccine.
为应对2019冠状病毒病（COVID-19）大流行，达到预定安全和疗效水平的疫苗在紧急使用授权/列入清单（EUA/EUL）下推出使用。截至目前，印度政府已引入三种疫苗用于紧急使用。
本研究旨在评估在接受逆转录-聚合酶链反应（RT-PCR）COVID-19检测的成年人（≥45岁）中，Covishield疫苗与COVID-19感染之间的关联。
本研究在印度东北部一个邦的一家专门的COVID-19医院对45岁及以上接受RT-PCR检测的成年人进行。病例为RT-PCR检测呈阳性者，对照为同期RT-PCR检测呈阴性者。使用结构化问卷收集有关社会人口学特征、COVID-19症状、疫苗接种状况、合并症等相关数据。采用多元逻辑回归计算比值比（OR），以发现疫苗接种与COVID-19感染之间的关联。
本研究共采访了116名45岁及以上的参与者。结果发现，与对照组相比，病例更有可能出现症状（48%对6.9%，P值=<0.005）且有家庭成员呈阳性的病史（89.7%对72.4%，P值=0.018）。有症状者感染COVID-19的几率为OR 12.60（95%置信区间（CI）4.03 - 39.34），未接种疫苗者为OR 6.07（95%CI 1.90 - 19.34）。
Covishield疫苗可保护个体免受COVID-19感染，接种疫苗的个体感染风险显著降低。对患者的意义：COVID-19疫苗接种可预防感染并消除对疫苗的误解。
